These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

648 related articles for article (PubMed ID: 18762933)

  • 21. Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.
    Johnsson G; Regàrdh CG
    Clin Pharmacokinet; 1976; 1(4):233-63. PubMed ID: 13958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction.
    Ferron GM; Preston RA; Noveck RJ; Pockros P; Mayer P; Getsy J; Turner M; Abell M; Paul J
    Clin Ther; 2001 Aug; 23(8):1180-92. PubMed ID: 11558857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimizing pediatric dosing: a developmental pharmacologic approach.
    Anderson GD; Lynn AM
    Pharmacotherapy; 2009 Jun; 29(6):680-90. PubMed ID: 19476420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Presystemic extraction: mechanisms and consequences.
    Greenblatt DJ
    J Clin Pharmacol; 1993 Jul; 33(7):650-6. PubMed ID: 8366190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment.
    Talal AH; Venuto CS; Younis I
    Clin Pharmacol Drug Dev; 2017 Mar; 6(2):206-212. PubMed ID: 28263464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.
    Emoto C; Murayama N; Rostami-Hodjegan A; Yamazaki H
    Curr Drug Metab; 2010 Oct; 11(8):678-85. PubMed ID: 20973757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
    Fenneteau F; Poulin P; Nekka F
    J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of liver metabolic function. Clinical implications.
    Brockmöller J; Roots I
    Clin Pharmacokinet; 1994 Sep; 27(3):216-48. PubMed ID: 7988103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic drug interactions in liver disease: An update.
    Palatini P; De Martin S
    World J Gastroenterol; 2016 Jan; 22(3):1260-78. PubMed ID: 26811663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function.
    O'Reilly S; Rowinsky E; Slichenmyer W; Donehower RC; Forastiere A; Ettinger D; Chen TL; Sartorius S; Bowling K; Smith J; Brubaker A; Lubejko B; Ignacio V; Grochow LB
    J Natl Cancer Inst; 1996 Jun; 88(12):817-24. PubMed ID: 8637048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Scaling Factors for Clearance in Adult Liver Cirrhosis.
    El-Khateeb E; Achour B; Scotcher D; Al-Majdoub ZM; Athwal V; Barber J; Rostami-Hodjegan A
    Drug Metab Dispos; 2020 Dec; 48(12):1271-1282. PubMed ID: 32978222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study.
    Kobalava Z; Villevalde S; Kotovskaya Y; Hinrichsen H; Petersen-Sylla M; Zaehringer A; Pang Y; Rajman I; Canadi J; Dahlke M; Lloyd P; Halabi A
    Br J Clin Pharmacol; 2015 Jun; 79(6):937-45. PubMed ID: 25511105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor.
    Sarapa N; Britto MR; Mainka MB; Parivar K
    Eur J Clin Pharmacol; 2005 Jun; 61(4):247-56. PubMed ID: 15887009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.
    Bartelink IH; Rademaker CM; Schobben AF; van den Anker JN
    Clin Pharmacokinet; 2006; 45(11):1077-97. PubMed ID: 17048973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of hepatic or renal impairment on eltrombopag pharmacokinetics.
    Bauman JW; Vincent CT; Peng B; Wire MB; Williams DD; Park JW
    J Clin Pharmacol; 2011 May; 51(5):739-50. PubMed ID: 20663991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modeling and predicting drug pharmacokinetics in patients with renal impairment.
    Rowland Yeo K; Aarabi M; Jamei M; Rostami-Hodjegan A
    Expert Rev Clin Pharmacol; 2011 Mar; 4(2):261-74. PubMed ID: 22115405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Pilot Study of Vinorelbine Safety and Pharmacokinetics in Patients with Varying Degrees of Liver Dysfunction.
    Gong J; Cho M; Gupta R; Synold TW; Frankel P; Ruel C; Fakih M; Chung V; Lim D; Chao J
    Oncologist; 2019 Aug; 24(8):1137-1145. PubMed ID: 30710067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs.
    Yuan R; Venitz J
    Int J Clin Pharmacol Ther; 2000 May; 38(5):245-53. PubMed ID: 10839468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
    Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
    Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.